Quantum BioPharma Appoints Leading MS Expert Dr. Jack Antel as Clinical Advisor for Lucid-MS Development
Quantum BioPharma has strengthened its multiple sclerosis program by appointing renowned neurologist Dr. Jack Antel to guide the clinical development of Lucid-21-302 as the investigational drug advances toward Phase 2 trials.
Quantum BioPharma Ltd. has appointed Dr. Jack Antel, a world-renowned multiple sclerosis expert and Professor of Neurology at McGill University, as clinical advisor to support the development of Lucid-21-302, the company's patented investigational drug designed to inhibit demyelination in MS. This strategic appointment signals significant advancement in Quantum BioPharma's multiple sclerosis program as the company prepares to advance Lucid-MS into Phase 2 clinical studies.
Dr. Antel brings substantial expertise to the role, having received the National Multiple Sclerosis Society and American Academy of Neurology's Dystel Award and authored over 450 published articles. His primary responsibility will involve guiding the design of efficacy trials for Lucid-MS, which represents a critical step in demonstrating the drug's potential clinical benefits. The appointment of such a distinguished expert underscores the scientific credibility of Quantum BioPharma's approach to treating multiple sclerosis.
Dr. Antel joins Dr. Peter Stys, Professor of Neurosciences at the University of Calgary, who continues to serve as clinical advisor, creating a formidable team of neurological experts overseeing the development of Lucid-MS. This dual advisory structure provides Quantum BioPharma with comprehensive guidance from leading authorities in multiple sclerosis research and treatment. The company's latest developments and updates are available through their corporate newsroom at https://ibn.fm/QNTM.
Lucid-MS represents a novel approach to multiple sclerosis treatment as a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Since demyelination constitutes the underlying mechanism of multiple sclerosis, a drug capable of inhibiting this process could potentially address the fundamental pathology of the disease rather than merely managing symptoms. The full details of the clinical advisory appointment can be reviewed in the official press release available at https://ibn.fm/NWMFj.
This development comes as Quantum BioPharma focuses on building a portfolio of innovative assets for treating challenging neurodegenerative and metabolic disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., the company maintains exclusive focus on the research and development of Lucid-MS. The progression into Phase 2 studies with enhanced clinical guidance represents a crucial milestone in validating the therapeutic potential of this investigational compound for multiple sclerosis patients worldwide.